PE20240021A1 - Dispersiones solidas amorfas - Google Patents
Dispersiones solidas amorfasInfo
- Publication number
- PE20240021A1 PE20240021A1 PE2023001827A PE2023001827A PE20240021A1 PE 20240021 A1 PE20240021 A1 PE 20240021A1 PE 2023001827 A PE2023001827 A PE 2023001827A PE 2023001827 A PE2023001827 A PE 2023001827A PE 20240021 A1 PE20240021 A1 PE 20240021A1
- Authority
- PE
- Peru
- Prior art keywords
- amorphous solid
- solid dispersions
- polymer matrix
- hypromellose
- vinyl
- Prior art date
Links
- 239000007962 solid dispersion Substances 0.000 title abstract 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 3
- 229960003943 hypromellose Drugs 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Oxide Ceramics (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Una dispersion solida caracterizada porque es de un compuesto de formula (I) y una matriz polimerica, en donde, la matriz polimerica se selecciona del grupo que consiste en acetato de hidroxipropil metil celulosa, copolimero N-vinil-2-pirrolidona/acetato de vinilo, polivinilpirrolidona, ftalato de hipromelosa e hipromelosa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20215253 | 2020-12-18 | ||
PCT/EP2021/086061 WO2022129267A1 (en) | 2020-12-18 | 2021-12-16 | Amorphous solid dispersions |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20240021A1 true PE20240021A1 (es) | 2024-01-04 |
Family
ID=73855649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023001827A PE20240021A1 (es) | 2020-12-18 | 2021-12-16 | Dispersiones solidas amorfas |
Country Status (15)
Country | Link |
---|---|
US (1) | US20240000769A1 (es) |
EP (1) | EP4262756A1 (es) |
JP (1) | JP2023553457A (es) |
KR (1) | KR20230121867A (es) |
CN (1) | CN116685308A (es) |
AR (1) | AR124406A1 (es) |
AU (1) | AU2021401128A1 (es) |
CA (1) | CA3201298A1 (es) |
CL (1) | CL2023001395A1 (es) |
CO (1) | CO2023007098A2 (es) |
IL (1) | IL303688A (es) |
MX (1) | MX2023007154A (es) |
PE (1) | PE20240021A1 (es) |
TW (1) | TW202241424A (es) |
WO (1) | WO2022129267A1 (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2978751B1 (en) * | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
EP3120871B1 (en) * | 2014-03-18 | 2023-06-28 | Takeda Pharmaceutical Company Limited | Solid dispersion |
SI3204359T1 (sl) * | 2014-10-08 | 2020-10-30 | UCB Biopharma SRL | Tetrahidroizokinolinski derivati |
US10370355B2 (en) * | 2016-04-13 | 2019-08-06 | Ucb Biopharma Sprl | Tetrahydroisoquinoline derivatives |
CA3139571A1 (en) | 2019-07-01 | 2021-01-07 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
-
2021
- 2021-12-16 EP EP21839495.5A patent/EP4262756A1/en active Pending
- 2021-12-16 KR KR1020237024337A patent/KR20230121867A/ko unknown
- 2021-12-16 TW TW110147172A patent/TW202241424A/zh unknown
- 2021-12-16 CN CN202180084509.7A patent/CN116685308A/zh active Pending
- 2021-12-16 PE PE2023001827A patent/PE20240021A1/es unknown
- 2021-12-16 US US18/267,925 patent/US20240000769A1/en active Pending
- 2021-12-16 JP JP2023535726A patent/JP2023553457A/ja active Pending
- 2021-12-16 MX MX2023007154A patent/MX2023007154A/es unknown
- 2021-12-16 IL IL303688A patent/IL303688A/en unknown
- 2021-12-16 AU AU2021401128A patent/AU2021401128A1/en active Pending
- 2021-12-16 WO PCT/EP2021/086061 patent/WO2022129267A1/en active Application Filing
- 2021-12-16 CA CA3201298A patent/CA3201298A1/en active Pending
- 2021-12-17 AR ARP210103551A patent/AR124406A1/es unknown
-
2023
- 2023-05-16 CL CL2023001395A patent/CL2023001395A1/es unknown
- 2023-05-30 CO CONC2023/0007098A patent/CO2023007098A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL303688A (en) | 2023-08-01 |
CA3201298A1 (en) | 2022-06-23 |
US20240000769A1 (en) | 2024-01-04 |
AR124406A1 (es) | 2023-03-22 |
EP4262756A1 (en) | 2023-10-25 |
CL2023001395A1 (es) | 2023-12-29 |
JP2023553457A (ja) | 2023-12-21 |
CO2023007098A2 (es) | 2023-06-09 |
CN116685308A (zh) | 2023-09-01 |
TW202241424A (zh) | 2022-11-01 |
KR20230121867A (ko) | 2023-08-21 |
MX2023007154A (es) | 2023-06-28 |
AU2021401128A1 (en) | 2023-07-13 |
WO2022129267A1 (en) | 2022-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2721059T3 (es) | Formulaciones que contienen dapagliflozina amorfa | |
EP4218735A3 (en) | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | |
RU2018146513A (ru) | Твердые формы венетоклакса и способы получения венетоклакса | |
JP2012236837A5 (es) | ||
AR071970A1 (es) | Composicion de liberacion pulsatil de sildenafil y proceso para prepararla | |
EA201892836A1 (ru) | Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением | |
AR102228A1 (es) | Una formulación de metformina de liberación sostenida y un método de preparación de la misma | |
JP2020079283A5 (es) | ||
JP2014208655A5 (es) | ||
PE20240021A1 (es) | Dispersiones solidas amorfas | |
SG11201806520XA (en) | Amphiphilic diblock copolymer and use of same for producing polymeric filter membranes | |
JP2019514993A5 (es) | ||
AR123453A1 (es) | Formulaciones de un modulador de somatostatina | |
MX371531B (es) | Formulaciones para el tratamiento de semillas. | |
AR121598A1 (es) | Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano | |
JP1736708S (ja) | 設定用画像 | |
MX2017000814A (es) | Composicion antiadherente a base de alcohol. | |
JP2011513393A5 (es) | ||
UY37550A (es) | Nueva formulación que comprende un derivado de bencimidazol | |
JP2015221782A5 (es) | ||
RU2014145845A (ru) | Таблетка с замедленным высвобождением, содержащая леводропропизин и способ ее изготовлеия | |
JP2017506265A5 (es) | ||
NZ705802A (en) | Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it. | |
WO2021262426A3 (en) | Adamantane amides and thioamides for the treatment of ebolavirus infection | |
RU2020109948A (ru) | Экструдированные композиции энзалутамида |